VetMedAtopic dermatitis in dogs: does topical hydrocortisone aceponate spray control flares and reduce systemic drug use versus placebo? — LIKELY
In dogs with atopic dermatitis, does topical hydrocortisone aceponate spray vs placebo control localised flares and reduce systemic drug use?
Shelf #496 · gate-verified and displayed under the developer's blinded-trial rule
LIKELY: In dogs with atopic dermatitis, 0.0584% hydrocortisone aceponate (HCA) spray beat placebo on lesion and itch scores in a randomised, double blind, placebo-controlled trial (Nuttall 2009: 28 dogs with CADESI-03 scores of 50 or more; at day 28 CADESI had fallen 61.4% on HCA versus 13.4% on placebo, P = 0.0069, and pruritus 38.8% versus a 57.6% rise on placebo, P = 0.0015), and proactive twice-weekly application after remission more than tripled the median time to relapse in a randomised, double-blind, placebo-controlled pilot trial (Lourenço 2016: median 115 days versus 33 days, P < 0.0001, 41 dogs). A third small randomised, double-blinded, placebo-controlled trial (Takahashi 2021, 18 dogs, all receiving systemic oclacitinib) found that adding HCA spray prevented the rebound in lesion and pruritus scores seen on placebo spray when oclacitinib was tapered from twice to once daily. Design class (a): randomisation and double-blinding are established by the carded records' own wording and MeSH (Double-Blind Method on all three records). The scope limits are stated plainly: no carded trial measured systemic drug dose or dose reduction as an endpoint, so the 'reduce systemic drug use' half of the question is supported only indirectly — by flare prevention (Lourenço) and by maintained control during a systemic taper (Takahashi) — not by a steroid- or oclacitinib-sparing trial of the spray itself; the flare trials treated atopic dermatitis generally rather than only localised lesions; samples are small (18–41 dogs); and the spray is not licensed for long-term treatment, as Nuttall 2009 itself notes. Consistent direction across three double-blind placebo-controlled trials with clinical (not surrogate) endpoints supports LIKELY, not PROBABLE. Drafted Nov 10, 2026 (VetMed build, topic #496); all figures from the abstract fetched and verified at drafting.
Nuttall 2009: hydrocortisone aceponate spray cut CADESI by 61.4% versus 13.4% on placebo at day 28 (P = 0.0069) and pruritus by 38.8% while placebo pruritus rose 57.6% (P = 0.0015) in 28 dogs with atopic dermatitis
Randomised, double blind, placebo-controlled trial (record's own wording: 'a randomised, double blind, placebo-controlled trial'; publication type: Randomized Controlled Trial)
Who: Dogs: client-owned dogs with canine atopic dermatitis and a canine AD extent and severity index (CADESI-03) score of 50 or more, in a multicentre clinical setting. Dogs were randomly allocated to 0.0584% hydrocortisone aceponate (HCA) spray (n = 15) or placebo spray (n = 13), applied as two sprays from 10 cm away to treat an area of 100 cm², once daily for 28 days. Twenty-one of the dogs then received HCA spray once daily, reducing to every other day or twice weekly over 42 days if improvement was maintained. CADESI, pruritus (14 cm visual analogue scale) and owner satisfaction (5-point scale) were recorded every 14 days; haematology, biochemistry and adrenocorticotrophic hormone stimulation were performed at baseline, day 28 and day 70 (HCA n = 9; placebo n = 7). Intention-to-treat data were analysed.
Result: HCA spray significantly decreased CADESI (-61.4% versus -13.4%, P = 0.0069) and pruritus (-38.8% versus +57.6%, P = 0.0015) at day 28 compared to placebo. Scores were significantly decreased at day 14 (CADESI -50.5%, P < 0.0021) and day 28 (CADESI P < 0.0001; pruritus P = 0.018) compared to baseline following HCA but not placebo. At day 28, 11 of 15 HCA dogs had ≥50% reductions in CADESI and 7 of 15 in pruritus, compared to 3 of 13 (P = 0.02) and 1 of 13 (P = 0.04) placebo dogs. Owner satisfaction scores were significantly higher in the HCA group (day 28 P = 0.0001). In the 42-day maintenance phase, of the 21 dogs, 3 required daily maintenance therapy, 7 every other day, 6 twice weekly and 5 required additional therapy. Coat length did not influence the results. No adverse effects or changes to blood parameters were noted. The authors conclude HCA spray proved safe and effective up to 70 days, and note it is not licensed for long-term treatment.
Watch out: Small trial (15 versus 13 dogs) in moderately to severely affected dogs (CADESI-03 ≥50) treated over body areas of 100 cm² — not a trial of small localised flares only, and the 42-day maintenance phase had no placebo comparator, so the maintenance frequencies (daily to twice weekly) are descriptive, not controlled evidence. Five of 21 maintenance dogs still required additional therapy. Percents are mean score changes; the responder counts (11/15 versus 3/13 for CADESI) are the absolute rates behind them. The product studied is the licensed 0.0584% HCA spray formulation; results should not be transferred to other topical glucocorticoid preparations.
Nuttall T, Mueller R, Bensignor E, Verde M, Noli C, Schmidt V, Rème C. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol. 2009;20(3):191-8. PMID: 19374721. Registry ID: none in the record. MeSH: Animals · Dermatitis, Atopic/drug therapy, veterinary* · Dermatologic Agents/administration & dosage, therapeutic use* · Dog Diseases/drug therapy* · Dogs · Double-Blind Method · Female · Follow-Up Studies · Hydrocortisone/administration & dosage, analogs & derivatives*, therapeutic use · Male · Pruritus/drug therapy, veterinary · Severity of Illness Index · Treatment Outcome
Lourenço 2016: proactive hydrocortisone aceponate spray on 2 consecutive days each week delayed relapse of atopic dermatitis — median 115 days versus 33 days on placebo (P < 0.0001) in 41 dogs
Randomised, placebo-controlled, double-blinded clinical pilot trial (record's own wording: 'a randomised, placebo-controlled, double-blinded clinical trial'; publication type: Randomized Controlled Trial)
Who: Dogs: 41 client-owned dogs with spontaneous atopic dermatitis in a clinical setting. This pilot study was a randomised, placebo-controlled, double-blinded clinical trial with treatment failure as the end-point. Dogs were first treated once daily to remission, then randomly assigned to 0.0584% hydrocortisone aceponate spray (n = 21) or placebo spray (n = 20) on two consecutive days each week. All dogs were on appropriate flea control; no topical or systemic anti-inflammatory or antimicrobial agents were permitted. At day 0 all dogs were in remission or had mild atopic dermatitis by CADESI-03 score. Intention-to-treat analysis was used; the outcome was time to relapse.
Result: The time to relapse was significantly higher in the HCA group (median 115 days; range 31–260 days) compared to the placebo group (median 33 days; range 15–61 days) (P < 0.0001). No adverse events were attributable to the HCA spray. Four dogs were lost to follow-up and four were withdrawn after receiving prohibited medication. The authors conclude proactive long-term therapy of canine atopic dermatitis with an HCA spray administered on two consecutive days each week is effective and well-tolerated.
Watch out: A pilot study (21 versus 20 dogs) whose dogs entered in remission or with mild disease after an initial once-daily treatment phase — it tests flare prevention (proactive therapy), not treatment of an active severe flare, and 8 of 41 dogs left the analysis pathway (4 lost to follow-up, 4 withdrawn for prohibited medication). Because no other anti-inflammatory or antimicrobial therapy was permitted, the trial shows flares can be delayed without systemic drugs, but it did not measure systemic drug consumption, so it cannot by itself prove a systemic-drug-sparing effect.
Lourenço AM, Schmidt V, São Braz B, Nóbrega D, Nunes T, Duarte-Correia JH, Matias D, Maruhashi E, Rème CA, Nuttall T. Efficacy of proactive long-term maintenance therapy of canine atopic dermatitis with 0.0584% hydrocortisone aceponate spray: a double-blind placebo controlled pilot study. Vet Dermatol. 2016;27(2):88-92e25. PMID: 26804943. Registry ID: none in the record. MeSH: Administration, Topical · Animals · Anti-Inflammatory Agents/administration & dosage, therapeutic use* · Dermatitis, Atopic/drug therapy* · Dog Diseases/drug therapy* · Dogs · Double-Blind Method · Drug Administration Schedule · Hydrocortisone/administration & dosage, analogs & derivatives*, therapeutic use · Pilot Projects
Takahashi 2021: adding hydrocortisone aceponate spray prevented rebound during oclacitinib taper — day 28 mean reductions 56.0% (CADESI-4) and, at day 21, 59.9% (pruritus) versus 30.5% and 27.6% on placebo spray in 18 dogs, all on oclacitinib
Randomized, double-blinded, placebo-controlled trial (record's own wording: 'a randomized, double-blinded, placebo-controlled trial'; publication type: Randomized Controlled Trial, Veterinary) — of HCA spray versus placebo spray as an add-on to systemic oclacitinib in both arms
Who: Dogs: 18 dogs with atopic dermatitis in a clinical setting. All dogs were treated with systemic oclacitinib 0.4–0.6 mg/kg twice daily for 14 days, then once daily for 14 days, and were randomised to receive either 0.0584% hydrocortisone aceponate spray or placebo spray, applied once daily for 7 days then every other day through day 28. Clinical assessments were the Canine Atopic Dermatitis Extent and Severity Index, 4th iteration (CADESI-4) and the pruritus Visual Analog Scale (PVAS) every 7 days, with blood and urine tests every 14 days.
Result: Mean CADESI-4 and PVAS scores were significantly reduced on day 7 and day 14 compared to day 0 in both groups (P < 0.05). From day 14 to day 21, CADESI-4 and PVAS scores were significantly increased in the placebo group (P < 0.005), and not in the HCA-treated group. The mean reduction from baseline in the HCA-treated group was significantly higher than in the placebo group for PVAS on day 21 (59.9% versus 27.6%, P = 0.0216) and for CADESI-4 on day 28 (56.0% versus 30.5%, P = 0.0109). One dog in the HCA-treated group was withdrawn after developing diarrhoea. The authors conclude topical 0.0584% HCA spray may be useful for preventing exacerbation of pruritus and clinical lesions when tapering oclacitinib therapy in dogs with atopic dermatitis.
Watch out: Combination-therapy design: every dog received oclacitinib, so this record isolates the spray's added effect only in the setting of a systemic drug being tapered — it does not test the spray alone, and the early improvement (days 7–14) occurred in both groups on full-dose oclacitinib. Very small (18 dogs, group sizes not stated in the abstract), 28 days only. It supports the 'maintain control while systemic therapy is reduced' idea but measured scores, not the amount of systemic drug dogs ultimately needed.
Takahashi J, Kanda S, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Momiyama S, Nishiyama S, Motegi T, Iyori K. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial. Vet Dermatol. 2021;32(2):119-e25. PMID: 33185330. Registry ID: none in the record. MeSH: Animals · Dermatitis, Atopic*/drug therapy, veterinary · Dermatologic Agents*/adverse effects · Dog Diseases*/drug therapy · Dogs · Double-Blind Method · Hydrocortisone/analogs & derivatives · Pyrimidines · Sulfonamides
Synthesis: hydrocortisone aceponate spray controls atopic dermatitis versus placebo and delays flares on proactive use — LIKELY; direct evidence that it reduces systemic drug use was not found
Synthesis
Who: Synthesis of the cards above: Nuttall 2009 (28 dogs, CADESI-03 ≥50, spray versus placebo once daily for 28 days plus an uncontrolled 42-day maintenance phase), Lourenço 2016 (41 dogs in remission, proactive spray versus placebo on 2 consecutive days weekly, time to relapse) and Takahashi 2021 (18 dogs, spray versus placebo spray added to systemic oclacitinib with a mid-trial taper).
Result: (1) Active treatment: CADESI change at day 28 was -61.4% on HCA versus -13.4% on placebo (P = 0.0069); pruritus -38.8% versus +57.6% (P = 0.0015); ≥50% CADESI responders 11/15 versus 3/13 (Nuttall). (2) Flare prevention: median time to relapse 115 days on proactive HCA versus 33 days on placebo (P < 0.0001; Lourenço). (3) During systemic taper: scores rebounded significantly on placebo spray but not on HCA spray after oclacitinib was halved, with day 28 CADESI-4 reductions of 56.0% versus 30.5% (P = 0.0109; Takahashi). (4) Systemic drug use itself: no carded record measured it as an endpoint.
Watch out: Two records were deliberately not carded as claim-carriers: Bizikova 2010 (PMID: 20187913), a placebo-controlled experimental study in 10 Maltese-beagle atopic dogs measuring suppression of intradermal histamine and anti-IgE wheal reactions — a surrogate challenge model, not clinical flares (it also recorded reduced dermal thickness after 14 days of application, a skin-atrophy caution for prolonged use); and Nam 2012 (PMID: 22705741), an uncontrolled before-and-after study in 21 dogs with no comparator. Nothing here covers other topical glucocorticoids, other HCA formulations, or use beyond the studied durations, and the spray's long-term use remains outside its licence as noted on the Nuttall card. One-home note: essential fatty acid supplements for atopic dermatitis home in Shelf #279 and are not re-carded here.
Synthesis of Nuttall T et al. PMID: 19374721; Lourenço AM et al. PMID: 26804943; Takahashi J et al. PMID: 33185330. Registry IDs as on the individual cards.
Back to the library index · VetMed home
VetMed is an educational resource, not veterinary advice.